https://orcid.org/0000-0002-0912-4515
Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Ilias Karaiskos, Irene Galani, Vassiliki Papoutsaki, Lamprini Galani & Helen Giamarellou. (2022) Carbapenemase producing Klebsiella pneumoniae: implication on future therapeutic strategies. Expert Review of Anti-infective Therapy 20:1, pages 53-69.
Read now
Read now
Júlia Sellarès-Nadal, Simeón Eremiev, Joaquin Burgos & Benito Almirante. (2021) An overview of cilastatin + imipenem + relebactam as a therapeutic option for hospital-acquired and ventilator-associated bacterial pneumonia: evidence to date. Expert Opinion on Pharmacotherapy 22:12, pages 1521-1531.
Read now
Read now
Articles from other publishers (20)
Helio S. Sader, Rodrigo E. Mendes, Leonard Duncan, John H. Kimbrough, Cecilia G. Carvalhaes & Mariana Castanheira. (2023) Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018–2022). Diagnostic Microbiology and Infectious Disease 106:2, pages 115945.
Crossref
Crossref
Marta Palombo, Federica Bovo, Stefano Amadesi & Paolo Gaibani. (2023) Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria. Antibiotics 12:5, pages 858.
Crossref
Crossref
Shiv Dhiman, Danyel Ramirez, Yanqi Li, Ayush Kumar, Gilbert Arthur & Frank Schweizer. (2023)
Chimeric Tobramycin-Based Adjuvant TOB-TOB-CIP Potentiates Fluoroquinolone and β-Lactam Antibiotics against Multidrug-Resistant
Pseudomonas aeruginosa
. ACS Infectious Diseases 9:4, pages 864-885.
Crossref
Crossref
Varshaa Arer & Debasish Kar. (2023) Biochemical exploration of β-lactamase inhibitors. Frontiers in Genetics 13.
Crossref
Crossref
Stephen J. Wood, Timothy M. Kuzel & Sasha H. Shafikhani. (2023) Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics. Cells 12:1, pages 199.
Crossref
Crossref
Federica Bovo, Donatella Lombardo, Tiziana Lazzarotto, Simone Ambretti & Paolo Gaibani. (2022) Epidemiology and In Vitro Activity of Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam against KPC-Producing K. pneumoniae Collected from Bacteremic Patients, 2018 to 2020. Antibiotics 11:11, pages 1621.
Crossref
Crossref
Marta Hernández-García, María García-Castillo, José Melo-Cristino, Margarida F Pinto, Elsa Gonçalves, Valquíria Alves, Ana Raquel Vieira, Elmano Ramalheira, Luísa Sancho, José Diogo, Rui Ferreira, Hugo Cruz, Catarina Chaves, Germán Bou, Emilia Cercenado, Mercedes Delgado-Valverde, Antonio Oliver, Cristina Pitart, Jesús Rodríguez-Lozano, Nuria Tormo, Jazmín Díaz-Regañón, Leonor Pássaro, Joana Duarte, Rafael Cantón, Antonio Oliver, Xavier Mulet, Emilia Cercenado, Germán Bou, M Carmen Fernández, Álvaro Pascual, Mercedes Delgado, Concepción Gimeno, Nuria Tormo, Jorge Calvo, Jesús Rodríguez-Lozano, Ana Ávila Alonso, Jordi Vila, Francesc Marco, Cristina Pitart, María García del Castillo, Sergio García-Fernández, Marta Hernández-García, Rafael Cantón & Jazmín Díaz-Regañón. (2022)
In vitro
activity of imipenem/relebactam against
Pseudomonas aeruginosa
isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies)
. Journal of Antimicrobial Chemotherapy 77:11, pages 3163-3172.
Crossref
Crossref
Marta Hernández-García, María García-Castillo, Germán Bou, Emilia Cercenado, Mercedes Delgado-Valverde, Antonio Oliver, Cristina Pitart, Jesús Rodríguez-Lozano, Nuria Tormo, José Melo-Cristino, Margarida F. Pinto, Elsa Gonçalves, Valquíria Alves, Ana Raquel Vieira, Elmano Ramalheira, Luísa Sancho, José Diogo, Rui Ferreira, Hugo Cruz, Catarina Chaves, Joana Duarte, Leonor Pássaro, Jazmín Díaz-Regañón & Rafael Cantón. (2022)
Imipenem-Relebactam Susceptibility in
Enterobacterales
Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies)
. Microbiology Spectrum 10:5.
Crossref
Crossref
Nicola Coppola, Alberto Enrico Maraolo, Lorenzo Onorato, Riccardo Scotto, Federica Calò, Luigi Atripaldi, Anna Borrelli, Antonio Corcione, Maria Giovanna De Cristofaro, Emanuele Durante-Mangoni, Amelia Filippelli, Gianluigi Franci, Maria Galdo, Gaspare Guglielmi, Pasquale Pagliano, Alessandro Perrella, Ornella Piazza, Marco Picardi, Rodolfo Punzi, Ugo Trama & Ivan Gentile. (2022) Epidemiology, Mechanisms of Resistance and Treatment Algorithm for Infections Due to Carbapenem-Resistant Gram-Negative Bacteria: An Expert Panel Opinion. Antibiotics 11:9, pages 1263.
Crossref
Crossref
Paolo Gaibani, Tommaso Giani, Federica Bovo, Donatella Lombardo, Stefano Amadesi, Tiziana Lazzarotto, Marco Coppi, Gian Maria Rossolini & Simone Ambretti. (2022) Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing. Antibiotics 11:5, pages 628.
Crossref
Crossref
Silvana Alfei & Anna Maria Schito. (2022) β-Lactam Antibiotics and β-Lactamase Enzymes Inhibitors, Part 2: Our Limited Resources. Pharmaceuticals 15:4, pages 476.
Crossref
Crossref
Emilio Bouza & Almudena Burillo. (2022) Current international and national guidelines for managing skin and soft tissue infections. Current Opinion in Infectious Diseases 35:2, pages 61-71.
Crossref
Crossref
Silvana Alfei & Guendalina Zuccari. (2022) Recommendations to Synthetize Old and New β-Lactamases Inhibitors: A Review to Encourage Further Production. Pharmaceuticals 15:3, pages 384.
Crossref
Crossref
Marta Hernández-García, María García-Castillo, Patricia Ruiz-Garbajosa, Germán Bou, María Siller-Ruiz, Cristina Pitart, Irene Gracia-Ahufinger, Xavier Mulet, Álvaro Pascual, Nuria Tormo & Rafael Cantón. (2022)
In Vitro
Activity of Cefepime-Taniborbactam against Carbapenemase-Producing
Enterobacterales
and Pseudomonas aeruginosa Isolates Recovered in Spain
. Antimicrobial Agents and Chemotherapy 66:3.
Crossref
Crossref
Ranganathan N. Iyer. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
3
63
.
Karl A. Glen & Iain L. Lamont. (2021) β-lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects. Pathogens 10:12, pages 1638.
Crossref
Crossref
Kathleen Tompkins & David van Duin. (2021) Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions. European Journal of Clinical Microbiology & Infectious Diseases 40:10, pages 2053-2068.
Crossref
Crossref
Davide Carcione, Claudia Siracusa, Adela Sulejmani, Valerio Leoni & Jari Intra. (2021) Old and New Beta-Lactamase Inhibitors: Molecular Structure, Mechanism of Action, and Clinical Use. Antibiotics 10:8, pages 995.
Crossref
Crossref
Corneliu Ovidiu Vrancianu, Elena Georgiana Dobre, Irina Gheorghe, Ilda Barbu, Roxana Elena Cristian & Mariana Carmen Chifiriuc. (2021) Present and Future Perspectives on Therapeutic Options for Carbapenemase-Producing Enterobacterales Infections. Microorganisms 9:4, pages 730.
Crossref
Crossref
Geneva M. Wilson, Margaret A. Fitzpatrick, Kyle Walding, Beverly Gonzalez, Marin L. Schweizer, Katie J. Suda & Charlesnika T. Evans. (2021) Evaluating the clinical effectiveness of new beta-lactam/beta-lactamase inhibitor combination antibiotics: A systematic literature review and meta-analysis. Antimicrobial Stewardship & Healthcare Epidemiology 1:1.
Crossref
Crossref